Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease


Loss of cell cycle control is a hallmark of cancer, and aberrations in the cyclin-CDK-RB (cyclin-dependent kinase-retinoblastoma protein) pathway are common in breast cancer. Consequently, inhibition of this pathway is an attractive therapeutic strategy, but results from clinical trials of CDK inhibitors in breast cancer have been disappointing. A recent study now shows that in cell culture a selective CDK4/6 inhibitor is preferentially effective in estrogen receptor-positive (ER+) disease and apparently acts synergistically with tamoxifen or trastuzumab. These exciting new preclinical data set the scene for a more targeted approach to further clinical evaluation wherein this class of drugs is targeted to subgroups of ER+ patients, including those with resistance to endocrine therapy, alone or in combination with current standard therapies.

Type Journal
ISBN 1465-542X (Electronic) 1465-542X (Linking)
Authors Sutherland, R.L.; Musgrove, E.A.
Responsible Garvan Author (missing name)
Published Date 2009-12-07
Published Volume 11
Published Issue 6
Published Pages 112
Status Published in-print
DOI bcr2454 [pii] 10.1186/bcr2454
URL link to publisher's version
OpenAccess link to author's accepted manuscript version